Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Rx Image Troubles Reflect Flaws In Health Insurance Coverage, Lilly CEO Says

  • News

Executive Summary

A better health insurance system would help the image of the pharmaceutical industry, Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

You may also be interested in...



Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities

Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy

Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities

Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy

Rx Access PR Effort Needs Hiatus, Pfizer Says; Roche Wants To Get Personal

Industry should take a hiatus from public relations messages that advocate patient access to drugs, Pfizer VP-Corporate Affairs Robert Mallett said at the Pharmaceutical Leadership Forum Conference in Washington, D.C. Nov. 18

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS042806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By